一种新型PCSK9反感性寡核酸的种群药动力学
Oskar Clewe1, Dinko Rekić1, Angelica L Quartino1
1Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
British journal of clinical pharmacology
|March 20, 2024
概括
体重显著影响AZD8233的暴露,AZD8233是一种针对PCSK9.9的反感性寡核酸. 这一发现解释了亚洲人群中较高的Cmax,并为这种新型的降脂疗法提供了剂量策略.
科学领域:
- 药理动力学 药理动力学
- 氧核酸治疗药物 治疗药物
- 心血管疾病 心血管疾病
背景情况:
- AZD8233是一种反感性寡核酸 (ASO),旨在降低PCSK9水平.
- 它使用先进的cET化学和GalNAc3向肝脏吸收.
研究的目的:
- 描述AZD8233.3的种群药理动力学.
- 确定影响AZD8233暴露的因素,在健康志愿者和患有脱脂症的患者中.
主要方法:
- 使用了非线性混合效应建模 (NONMEM).
- 分析了4项1-2期研究中的219名参与者的3416个样本的数据.
主要成果:
- 一个具有第一阶吸收的两部分模型描述了AZD8233的药理动力学.
- 迈凯利斯-门动力学解释了Cmax与剂量的超比例增加.
- 体重,性别,eGFR和疾病状况影响了AZD8233的暴露.
结论:
- 体重是影响AZD8233暴露的主要共同变量.
- 这解释了亚洲人群中较高的Cmax,并支持个性化剂量.
相关概念视频
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
171
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
171
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
134
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
134
Nonlinear Pharmacokinetics: Overview
366
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
366
Analysis of Population Pharmacokinetic Data
254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
62
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
62
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38


